Innovation is nothing new to the Nordic region, making the new alliance between the Johnson & Johnson Innovation and Karolinska Institutet an intuitive match. As part of this collaboration, Johnson & Johnson Innovation’s London team has established a life science hub at Karolinska Institutet to accelerate and progress the translation of promising science by providing emerging life science companies with investment and access to a wide range of resources and expertise across the Johnson & Johnson Family of Companies.
Karolinska Institutet was founded in 1810 as an "academy for the training of skilled army surgeons." Today it is one of the world’s leading medical universities and the home of the Nobel Prize in Physiology or Medicine. Karolinska Institutet has strategically positioned itself at the front line of exploration in several scientific fields and also has existing external collaborations with universities and companies worldwide.
Even before this alliance was announced, Johnson & Johnson Innovation had initiated an exciting collaboration with researchers at Karolinska Institutet towards disease interception in Rheumatoid Arthritis (RA). This collaboration focuses on increasing our understanding of disease initiation and progression and generating early biomarkers of disease and new drug targets.
Johnson & Johnson Innovation focuses on accelerating early-stage science worldwide. We do this by establishing collaborations with entrepreneurs and innovators around the world and providing them access to resources and expertise from across the Johnson & Johnson Family of Companies. Proximity – being on the ground to engage in the local life science ecosystem - is a key enabler of this strategy. This new collaboration will establish an office at Karolinska Institutet’s and a heightened presence in the region. Karolinska Institutet will act as a platform for exciting opportunities stemming from Karolinska Institutet as well as throughout the Nordic region.
The alliance calls for knowledge exchange, establishment of scouting programs, investment to advance ideas towards proof of concept, and seed financing for new company formation.
This collaboration is a great example of an emerging type of relationship between academia and industry; a relationship that allows for a broad, flexible and ever evolving approach toward innovation. By establishing a dynamic interface between our organizations we can combine and leverage our respective expertise to advance new ideas, technologies, and healthcare products with the potential to positively impact human health in the Nordic region and beyond.